SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- scarring, fibrosis, adhesions, keloids
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject10/7/2003 11:28:52 AM
From: nigel bates  Read Replies (1) of 32
 
Renovo / TGFß3

newscientist.com
...At a meeting at the Royal Society in London, UK, last week, Ferguson reported results of the first clinical trials of TGFß3. The experiments involved making two separate wounds in volunteers' arms. One wound was injected with the drug while the other was injected with a placebo. Ferguson says the final product might be given as a cream or injected into the bloodstream.

To date, the drug has been tried on just over 300 volunteers. It does not always prevent scarring, Ferguson says, but it does reduce it. And it also dramatically speeds up healing...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News